Related Experiment Video

Updated: Jul 13, 2026

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring
08:45

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

Clearing the TRAIL for Cancer Therapy

Mark A Hall1, John L Cleveland

  • 1Department of Cancer Biology, The Scripps Research Institute-Florida, Jupiter, FL 334548, USA.

Cancer Cell
|July 7, 2007
PubMed

Insights

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows anticancer promise but can be blocked by NF-kappaB activation. Myc and Sorafenib overcome this resistance by reducing Mcl-1, enhancing TRAIL

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling Pathways

Background:

  • The death receptor ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a promising anticancer agent.
  • TRAIL signaling can activate NF-kappaB, leading to the induction of antiapoptotic proteins Mcl-1 and cIAP2, which reduce TRAIL's efficacy.
  • Colon cancer cells often exhibit resistance to TRAIL-induced apoptosis.

Discussion:

  • This study investigates mechanisms to overcome TRAIL resistance in colon cancer.
  • The Myc oncoprotein and the Raf kinase inhibitor Sorafenib were explored for their ability to sensitize TRAIL-resistant cells.
  • The research focuses on disrupting survival signaling pathways that counteract TRAIL's apoptotic effects.

Key Insights:

  • Myc and Sorafenib sensitize TRAIL-resistant colon cancer cells by inhibiting NF-kappaB-mediated transcription of Mcl-1.
  • NF-kappaB activation is a key mechanism conferring resistance to TRAIL therapy.
  • Reducing Mcl-1 expression is crucial for restoring TRAIL sensitivity.

Outlook:

  • Combining TRAIL with agents that inhibit NF-kappaB signaling or directly target Mcl-1 may offer therapeutic benefits.
  • Further research into combination therapies could enhance the clinical utility of TRAIL.
  • Targeting survival pathways alongside apoptosis-inducing agents presents a promising strategy for cancer treatment.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...